Yazarlar : Melchardt T, Weiss L, Hufnagl C et al

Yayın : Leuk Lymphoma

Yayın Yılı : 2014

Pubmed Linki : http://www.docguide.com/treatment-aggressive-b-cell-lymphoma-elderly-patients-influence-snps-affecting-pharmacodynamics-chem?tsid=5

Konu : Geriyatrik Hematoloji

Literatür İçeriği : Clinical and/or biological risk factors are needed to identify elderly patients with aggressive B-cell lymphoma able to receive full dose R-CHOP treatment. We present a retrospective analysis of 83 patients>75 years of age (range:75-97) that were diagnosed with aggressive B cell lymphoma between 2004 and 2011 in our clinic. R-CHOP-like therapy was administered in 82% of these patients resulting in a median overall survival of 54 months. A median cumulative dose of 226mg/m(2) doxorubicin and a median of 6 cycles were applied in these patients. Two genotypes of the CBR3 and the MLH1 genes affecting the metabolism of cytostatics identified a subgroup with a favorable prognosis (median overall survival not reached vs 30 months p=0.01). A treatment strategy aiming at a full-dose R-CHOP was feasible and resulted in an encouraging treatment outcome in patients>75 years. Pharmacogenetic parameters, if independently validated, may be helpful in elderly patients.

Literatür Arşivi